Lucy Therapeutics

LuxyTx is excited to welcome Kim Drapkin as the Chair of our Board of Directors!

Rett syndrome is a #rare #neurological condition that affects around one in every 10,000 female births, with an even lower occurrence in males. Rett syndrome often goes unnoticed until a child is between 6 and 18 months old, when parents and doctors may observe missed developmental milestones or regression of previously acquired skills. Individuals with #rettsyndrome face significant challenges in their ability to speak, walk, eat, and even breathe easily. We invite you to join us in raising #awareness and supporting the Rett syndrome #community. To learn more about Rett syndrome and how you can help, visit the International Rett Syndrome Foundation at rettsyndrome.org. #rettsyndromeawarenessmonth #research #raredisease #drugdiscovery #IRSF #LucyTx

LucyTx is looking for a Research Associate to join our #team! The ideal #candidate will possess a strong background in biological sciences, with expertise in mammalian #cellculture and #molecularbiology techniques such as ELISAs, Western blotting, and qPCR. #research #sciencejobs #scientist https://lnkd.in/epeN8Adu

Join our team! #lifescience #team #executiveassistant #science

We are honored to be a finalist in the Biotech of the Year category of the BWB Awards 2024! Join our CEO, Dr. Amy Ripka and 300+ life science leaders for an evening of dinner, drinks, networking, entertainment, and the final results! See you on the red carpet! https://lnkd.in/d7mprxAh 

LucyTx is looking for an experienced Senior #Scientist to join our team! The ideal candidate will have a strong background in #neuroscience or mitochondrial diseases, with expertise in cell culture techniques and assay development for preclinical #drugdiscovery.

A great post from The Termeer Foundation featuring our Founder & CEO, Dr. Amy Ripka! #alzheimersdisease #brainawareness #mitochondria #science #research #lucytx

Research news 📣 We’re providing £1.6m through our Virtual Biotech programme to Lucy Therapeutics for development of a potential new treatment targeting mitochondria to protect brain cells in Parkinson’s patients, in partnership with The Michael J. Fox Foundation for Parkinson's Research . Read more 👉🏽 https://prksn.uk/3Rf5zLl

Kudos to Lucy Therapeutics, who recently announced they raised $12.5 million in additional funding led by existing and new investors. The company is working to develop novel therapies based on mitochondrial small-molecule treatments and diagnostic biomarkers for complex neurological diseases. Lucy Therapeutics is a previous MassNextGen awardee. The MLSC initiative is designed to support underrepresented entrepreneurs by providing them with a year-long customized package of support, which includes non-dilutive grant funding and access to a network of seasoned professionals from the life sciences ecosystem helping them to refine their business strategies and effectively raise capital. The program is currently accepting applications until June 14, 2024 at 4 p.m. EST. Learn more about Lucy Therapeutics: https://lnkd.in/eq8m_DFA Learn more about MassNextGen: https://lnkd.in/eRrzK8X

👏 Congratulations to the nine companies reporting new funding since our last #FundingFriday. Among them was #MassBioMember Lucy Therapeutics which announced recently raising $12.5 million in additional funding to further its research programs for Alzheimer’s and Parkinson's diseases and continue its development of a novel drug target for Rett syndrome. https://lnkd.in/eJ2JXKYe Modulate Bio | Purinomia Biotech | Aviceda Therapeutics | Sunflower Therapeutics | Vaxess Technologies | Aktis Oncology | Hopewell Therapeutics, Inc.